×
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
NASDAQ:CRSP

CRISPR Therapeutics (CRSP) Stock Forecast, Price & News

$58.34
+3.11 (+5.63%)
(As of 05/27/2022 04:00 PM ET)
Add
Compare
Today's Range
$54.49
$58.56
50-Day Range
$43.23
$69.51
52-Week Range
$42.51
$169.76
Volume
1.11 million shs
Average Volume
1.51 million shs
Market Capitalization
$4.52 billion
P/E Ratio
16.16
Dividend Yield
N/A
Beta
2.05
30 days | 90 days | 365 days | Advanced Chart
Receive CRSP News and Ratings via Email

Sign-up to receive the latest news and ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CRISPR Therapeutics logo

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRSP
Fax
N/A
Employees
473
Year Founded
N/A

Sales & Book Value

Annual Sales
$914.96 million
Cash Flow
$5.53 per share
Book Value
$28.98 per share

Profitability

Net Income
$377.66 million
Pretax Margin
34.58%

Debt

Price-To-Earnings

Miscellaneous

Free Float
69,169,000
Market Cap
$4.52 billion
Optionable
Optionable

Company Calendar

Last Earnings
5/09/2022
Today
5/28/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.02 out of 5 stars

Medical Sector

569th out of 1,424 stocks

Biological Products, Except Diagnostic Industry

90th out of 209 stocks

Analyst Opinion: 3.3Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -













CRISPR Therapeutics (NASDAQ:CRSP) Frequently Asked Questions

Is CRISPR Therapeutics a buy right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CRISPR Therapeutics in the last twelve months. There are currently 6 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CRISPR Therapeutics stock.
View analyst ratings for CRISPR Therapeutics
or view top-rated stocks.

When is CRISPR Therapeutics' next earnings date?

CRISPR Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for CRISPR Therapeutics
.

How were CRISPR Therapeutics' earnings last quarter?

CRISPR Therapeutics AG (NASDAQ:CRSP) posted its quarterly earnings results on Monday, May, 9th. The company reported ($2.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.94) by $0.38. The firm earned $0.94 million during the quarter, compared to analyst estimates of $2.45 million. CRISPR Therapeutics had a net margin of 34.04% and a trailing twelve-month return on equity of 12.77%. CRISPR Therapeutics's revenue was up 74.4% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.51) earnings per share.
View CRISPR Therapeutics' earnings history
.

What price target have analysts set for CRSP?

15 Wall Street analysts have issued 1 year price targets for CRISPR Therapeutics' stock. Their forecasts range from $46.00 to $220.00. On average, they anticipate CRISPR Therapeutics' share price to reach $114.71 in the next twelve months. This suggests a possible upside of 96.6% from the stock's current price.
View analysts' price targets for CRISPR Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are CRISPR Therapeutics' key executives?
CRISPR Therapeutics' management team includes the following people:
  • Dr. Rodger Novak M.D., Founder, Chairman & Pres (Age 55)
  • Dr. Samarth Kulkarni, CEO & Director (Age 43, Pay $1.18M) (LinkedIn Profile)
  • Dr. Lawrence Otto Klein Ph.D., Chief Operating Officer (Age 40, Pay $675k)
  • Mr. James R. Kasinger, Gen. Counsel & Sec. (Age 50, Pay $648.93k)
  • Mr. Shaun Foy, Founder
  • Dr. Emmanuelle Marie Charpentier, Co-Founder & Scientific Advisory Board Member
  • Dr. Craig C. Mello Ph.D., Scientific Founder & Advisory Board Member
  • Dr. Chad Cowan Ph.D., Scientific Founder
  • Dr. Matthew Porteus M.D., Ph.D., Scientific Founder & Advisory Board Member (Age 56)
  • Dr. Daniel G. Anderson Ph.D., Scientific Founder & Advisory Board Member
What other stocks do shareholders of CRISPR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CRISPR Therapeutics investors own include NVIDIA (NVDA), Editas Medicine (EDIT), Alibaba Group (BABA), Micron Technology (MU), Advanced Micro Devices (AMD), Square (SQ), Tesla (TSLA), Intellia Therapeutics (NTLA), QUALCOMM (QCOM) and Shopify (SHOP).

When did CRISPR Therapeutics IPO?

(CRSP) raised $75 million in an initial public offering on Wednesday, October 19th 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays served as the underwriters for the IPO and Guggenheim Securities was co-manager.

What is CRISPR Therapeutics' stock symbol?

CRISPR Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."

Who are CRISPR Therapeutics' major shareholders?

CRISPR Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (6.04%), Nikko Asset Management Americas Inc. (5.97%), Capital International Investors (4.65%), BlackRock Inc. (2.94%), Loomis Sayles & Co. L P (1.67%) and Vanguard Group Inc. (1.57%). Company insiders that own CRISPR Therapeutics stock include Bradley J Phd Bolzon, Bradley J Phd Bolzon, James R Kasinger, Lawrence Otto Klein, Michael John Tomsicek, Rodger Novak, Samarth Kulkarni and Tony W Ho.
View institutional ownership trends for CRISPR Therapeutics
.

Which institutional investors are selling CRISPR Therapeutics stock?

CRSP stock was sold by a variety of institutional investors in the last quarter, including Group One Trading L.P., Goldman Sachs Group Inc., Jane Street Group LLC, Bellevue Group AG, Carnegie Capital Asset Management LLC, FinTrust Capital Advisors LLC, Loomis Sayles & Co. L P, and Mirae Asset Global Investments Co. Ltd.. Company insiders that have sold CRISPR Therapeutics company stock in the last year include Bradley J Phd Bolzon, Michael John Tomsicek, Rodger Novak, and Samarth Kulkarni.
View insider buying and selling activity for CRISPR Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying CRISPR Therapeutics stock?

CRSP stock was acquired by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., BlackRock Inc., Vanguard Group Inc., Charles Schwab Investment Management Inc., Nikko Asset Management Americas Inc., State Street Corp, Woodline Partners LP, and Frontier Capital Management Co. LLC.
View insider buying and selling activity for CRISPR Therapeutics
or or view top insider-buying stocks.

How do I buy shares of CRISPR Therapeutics?

Shares of CRSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CRISPR Therapeutics' stock price today?

One share of CRSP stock can currently be purchased for approximately $58.34.

How much money does CRISPR Therapeutics make?

CRISPR Therapeutics has a market capitalization of $4.52 billion and generates $914.96 million in revenue each year. The company earns $377.66 million in net income (profit) each year or $3.609990 on an earnings per share basis.

How many employees does CRISPR Therapeutics have?

CRISPR Therapeutics employs 473 workers across the globe.

What is CRISPR Therapeutics' official website?

The official website for CRISPR Therapeutics is www.crisprtx.com.

How can I contact CRISPR Therapeutics?

CRISPR Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company can be reached via phone at (141) 561-3277 or via email at [email protected].

This page was last updated on 5/28/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.